20 June, 2024

Grand opening of CTC Netherlands early phase clinical unit on June 19

CTC Netherlands BV is excited to announce the official opening of a state-of-the-art early phase clinical unit with 12 beds on the premises of the University Medical Center Groningen (UMCG) on June 19, 2024.

“The clinic focuses on high-end early phase patient studies and early phase studies involving complex procedures, aiming to advance medical research and improve patient care, says Dr. Wim Tamminga, CEO CTC Netherlands. “We have strategic collaborations with UMCG’s Neurology, Psychiatry, and Anesthesiology departments, access to advanced imaging technologies, and the unique RecruitRX model for assessing trial feasibility.”

CTC Netherlands in Groningen was established in February 2024, as a subsidiary to Sweden-based Center for Translational Research (CTR), and part of the Sweden Site network of CTC Clinical Trials Consultants AB (CTC), a full service CRO with six clinics across Sweden. With the clinical unit opening in CTC Netherlands, CTC now has seven clinics and is able to offer full service projects within clinical phases 0-2.

The co-founders of CTC NL are CEO Dr. Wim Tamminga, COO Dr. Petra Schuilenga-Hut, and CPO Mariska Beukers-Reuvers, MSc.

“We are thrilled to be up and running with CTC Netherlands in Groningen. The exceptionally senior team of co-founders and the vibrant environment within UMCG will enable us to deliver early clinical trials in an efficient and sustainable way,” says Dr Karin Meyer, the CEO of Center for Translational Research, CTR.

Strategic Capabilities and Collaborations

CTC Netherlands BV’s clinical unit on the premises of the UMCG is uniquely positioned to leverage advanced medical resources and expertise, enhancing the scope and quality of its clinical trials.

Neurology Department: The collaboration with UMCG’s Neurology Department provides access to a substantial patient population suffering from neurodegenerative diseases such as Parkinson’s and Alzheimer’s, facilitating specialized early phase studies.

Psychiatry Department: By working closely with the Psychiatry Department, CTC Netherlands BV can conduct rigorous trials involving psychoactive drugs, essential for advancing mental health treatments.

Anesthesiology Department: The relationship with the Department of Anesthesiology supports trials requiring invasive cerebrospinal fluid (CSF) procedures, ensuring the highest standards of safety and expertise.

Imaging Center: Proximity to UMCG’s advanced imaging center, equipped with MRI and PET imaging technologies, allows for detailed and precise imaging studies, crucial for assessing drug effects and disease progression.

Introducing RecruitRX

A key differentiator for CTC Netherlands BV is its proprietary feasibility assessment model, RecruitRX. This innovative tool allows the company to accurately predict the feasibility of clinical trials, optimizing recruitment strategies and ensuring efficient study execution. RecruitRX leverages data analytics and patient demographics to streamline the trial process, enhancing the likelihood of successful study outcomes.

Dr. Wim Tamminga, CEO of CTC Netherlands BV, remarked, “Our collaboration with UMCG provides us with unparalleled capabilities to conduct comprehensive and high-quality clinical trials. This synergy is fundamental to our mission of advancing medical research and improving patient outcomes.”

Dr. Petra Schuilenga-Hut, COO, added, “The partnerships we have established with various UMCG departments, but also within other hospitals, private clinics and patient organizations in The Netherlands, empower us to work together optimally, allowing us to assist and complement each other in the best possible way. Together with our partners, we are committed to delivering reliable and impactful research.”

Drs. Mariska Beukers-Reuvers, CPO, emphasized, “As part of CTC Clinical Trial Consultants and CTR Sweden, along with our strategic location at the UMCG and the RecruitRX model, places us in an excellent position to set new benchmarks in clinical research. We are dedicated to advancing scientific knowledge and developing new therapies that can transform healthcare.”

CTC Netherlands BV is now operational and open for collaborations for groundbreaking clinical studies. For further information about our services and partnership opportunities, please visit www.ctc-netherlands.com.

About CTC Netherlands BV

CTC Netherlands BV is a clinical research organization specializing in early phase clinical trials, established by Dr. Wim Tamminga, Dr. Petra Schuilenga-Hut, and Drs. Mariska Beukers-Reuvers. The company operates a cutting-edge 12-bed clinical unit on the premises of the University Medical Center Groningen. CTC Netherlands BV focuses on high-end early phase patient studies and early phase studies involving complex procedures, aiming to advance medical research and improve patient care. The company benefits from strategic collaborations with UMCG’s Neurology, Psychiatry, and Anesthesiology departments, access to advanced imaging technologies, and the unique RecruitRX model for assessing trial feasibility.

About Center for Translational Research

CTR was founded in 2016 and is the holding company for a group of complementary life science service companies engaged in translational research. CTR is growing and has the ambition to continue to expand the group of qualified companies within development of both pharmaceuticals and medical devices. Today, the CTR companies include CTC Clinical Trial Consultants, Lablytica Life Science, RegSmart Life Science, Toxicology Knowledge Team, Metasafe, RegFile, QAlliance and CTC Netherlands.